NEPH (Nephros) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NEPH Nephros Inc NEPH
64 GF Score
Price $3.64
GF Value $2.89
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Nephros Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

NEPH
64GF Score
Nephros Inc NEPH
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Nephros (NEPH) Overvalued in 2026?

Based on GuruFocus' analysis, Nephros stock appears to be overvalued. The current stock price of $3.64 is trading 26% above its estimated GF Value™ of $2.89. GuruFocus considers Nephros to be Modestly Overvalued.

Key valuation signals for NEPH:

  • Short Ratio:
  • GF Value™: $2.89 vs. price of $3.64 (26% above fair value)
  • GF Score™: 64/100 with 5 warning signs

No single metric tells the full story. See the NEPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nephros Business Description

Other Exchanges NPJP:Germany
Address 380 Lackawanna Place, South Orange, NJ, USA, 07079
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of revenue from product sales and a small amount from royalty revenue and other revenues.
64GF Score

Get the complete analysis for NEPH

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.64
Price
$2.89
GF Value